Brief: Innate Pharma SA - ‍​First Patient Dosed In Phase 2 Matisse Trial Of Iph5201 In Early Stage Lung Cancer

Innate Pharma SA

26/06/2023 11:20

June 26 (Reuters) - Innate Pharma SA  IPH.PA :
    * INNATE PHARMA SA - ‍​FIRST PATIENT DOSED IN PHASE 2
MATISSE
TRIAL OF IPH5201 IN EARLY STAGE LUNG CANCER
    * INNATE PHARMA SA - IPH5201 IS DEVELOPED IN COLLABORATION
WITH
ASTRAZENECA

Source text for Eikon:  ID: 
Further company coverage:  IPH.PA 

 ((Reuters.Briefs@thomsonreuters.com;))